Biochemical Characterization of Cardiolipin Synthase Mutations Associated with Daptomycin Resistance in Enterococci

被引:59
作者
Davlieva, Milya [1 ]
Zhang, Wanna [1 ]
Arias, Cesar A. [2 ,3 ]
Shamoo, Yousif [1 ,4 ]
机构
[1] Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA
[2] Univ Texas Med Sch Houston, Div Infect Dis, Houston, TX USA
[3] Univ El Bosque, Mol Genet & Antimicrobial Resistance Unit, Bogota, Colombia
[4] Rice Univ, Dept Ecol & Evolutionary Biol, Houston, TX USA
关键词
STAPHYLOCOCCUS-AUREUS; MEMBRANE-PROTEINS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PHOSPHOLIPASE-D; NO ESKAPE; IN-VIVO; SUSCEPTIBILITY; EMERGENCE; BACTEREMIA;
D O I
10.1128/AAC.01743-12
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
Daptomycin (DAP) resistance in enterococci has been linked to mutations in genes that alter the cell envelope stress response (CESR) (liaFSR) and changes in enzymes that directly affect phospholipid homeostasis, and these changes may alter membrane composition, such as that of cardiolipin synthase (Cls). While Cls substitutions are observed in response to DAP therapy, the effect of these mutations on Cls activity remains obscure. We have expressed, purified, and characterized Cls enzymes from both Enterococcus faecium S447 (residues 52 to 482; Cls447a) and Enterococcus faecalis S613 (residues 53 to 483; Cls613a) as well as Cls variants harboring a single-amino-acid change derived from DAP-resistant isolates of E. faecium. E. faecium Cls447a and E. faecalis Cls613a are tightly associated with the membrane and copurify with their substrate, phosphatidylglycerol (PG), and product, cardiolipin (CL). The amount of PG that copurifies with Cls is in molar excess to protein, suggesting that the enzyme localizes to PG-rich membrane regions. Both Cls447a(H215R) and Cls447a(R218Q) showed an increase in V-max (mu M CL/min/mu M protein) from 0.16 +/- 0.01 to 0.26 +/- 0.02 and 0.26 +/- 0.04, respectively, indicating that mutations associated with adaptation to DAP increase Cls activity. Modeling of Cls447a to Streptomyces sp. phospholipase D indicates that the adaptive mutations Cls447a(H215R) and Cls447a(R218Q) are proximal to the phospholipase domain 1 (PLD1) active site and near the putative nucleophile H217. As mutations to Cls are part of a larger genomic adaptation process, increased Cls activity is likely to be highly epistatic with other changes to facilitate DAP resistance.
引用
收藏
页码:289 / 296
页数:8
相关论文
共 46 条
[1]
The rise of the Enterococcus: beyond vancomycin resistance [J].
Arias, Cesar A. ;
Murray, Barbara E. .
NATURE REVIEWS MICROBIOLOGY, 2012, 10 (04) :266-278
[2]
Genetic Basis for In Vivo Daptomycin Resistance in Enterococci [J].
Arias, Cesar A. ;
Panesso, Diana ;
McGrath, Danielle M. ;
Qin, Xiang ;
Mojica, Maria F. ;
Miller, Corwin ;
Diaz, Lorena ;
Tran, Truc T. ;
Rincon, Sandra ;
Barbu, E. Magda ;
Reyes, Jinnethe ;
Roh, Jung H. ;
Lobos, Elizabeth ;
Sodergren, Erica ;
Pasqualini, Renata ;
Arap, Wadih ;
Quinn, John P. ;
Shamoo, Yousif ;
Murray, Barbara E. ;
Weinstock, George M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10) :892-900
[3]
Natural products to drugs: daptomycin and related lipopeptide antibiotics [J].
Baltz, RH ;
Miao, V ;
Wrigley, SK .
NATURAL PRODUCT REPORTS, 2005, 22 (06) :717-741
[4]
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[5]
INVITRO AND INVIVO ACTIVITY OF LY 146032, A NEW CYCLIC LIPOPEPTIDE ANTIBIOTIC [J].
ELIOPOULOS, GM ;
WILLEY, S ;
REISZNER, E ;
SPITZER, PG ;
CAPUTO, G ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (04) :532-535
[6]
An efficient strategy for high-throughput expression screening of recombinant integral membrane proteins [J].
Eshaghi, S ;
Hedrén, M ;
Nasser, MIA ;
Hammarberg, T ;
Thornell, A ;
Nordlund, P .
PROTEIN SCIENCE, 2005, 14 (03) :676-683
[7]
INVITRO ACTIVITY OF LY146032 AGAINST STAPHYLOCOCCI, STREPTOCOCCI, AND ENTEROCOCCI [J].
FASS, RJ ;
HELSEL, VL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (05) :781-784
[8]
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus [J].
Fowler, Vance G., Jr. ;
Boucher, Helen W. ;
Corey, G. Ralph ;
Abrutyn, Elias ;
Karchmer, Adolf W. ;
Rupp, Mark E. ;
Levine, Donald P. ;
Chambers, Henry F. ;
Tally, Francis P. ;
Vigliani, Gloria A. ;
Cabell, Christopher H. ;
Link, Arthur Stanley ;
DeMeyer, Ignace ;
Filler, Scott G. ;
Zervos, Marcus ;
Cook, Paul ;
Parsonnet, Jeffrey ;
Bernstein, Jack M. ;
Price, Connie Savor ;
Forrest, Graeme N. ;
Faetkenheuer, Gerd ;
Gareca, Marcelo ;
Rehm, Susan J. ;
Brodt, Hans Reinhardt ;
Tice, Alan ;
Cosgrove, Sara E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07) :653-665
[9]
Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus [J].
Friedman, L ;
Alder, JD ;
Silverman, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2137-2145
[10]
Green Myke R, 2006, J Oncol Pharm Pract, V12, P179, DOI 10.1177/1078155206069165